CLARINEX
LOE ApproachingNDAORALSOLUTION
Approved
Sep 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
CLARINEX by Merck & Co. is 1 -receptor histamine antagonist activity. First approved in 2004.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLARINEX (desloratadine) is an oral antihistamine solution approved in 2004 for allergic rhinitis that works as a selective H1-receptor antagonist with minimal central nervous system penetration. The formulation combines desloratadine with pseudoephedrine sulfate to provide both antihistamine and decongestant effects for symptom relief.
$0.289MPart D
LOE ApproachingDeclining
With LOE approaching and modest Part D spending ($289K in 2023), the brand team is likely in cost-containment and transition-planning mode, signaling limited headcount growth.
Mechanism of Action
1 -receptor histamine antagonist activity. Receptor binding data indicate that at a concentration of 2 to 3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 receptor. Desloratadine inhibited histamine release from human mast cells in vitro . Results of a…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CLARINEX offers stable, but declining, career opportunity within a mature, competitive market segment. This role is best suited for pharma professionals seeking experience in legacy product management, generic defense strategies, and transition planning rather than growth or innovation.
Worked on CLARINEX at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.